These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 3910219)

  • 21. Toxicological and tumoricidal evaluations of a new platinum complex, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato+ ++)platinum( II) monohydrate, in rats.
    Akamatsu K; Endo K; Matsumoto T; Morikawa K; Koizumi M; Koizumi K; Mitsui H
    Jpn J Cancer Res; 1991 Jun; 82(6):724-31. PubMed ID: 1906857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overview of carboplatin: replacing, complementing, and extending the therapeutic horizons of cisplatin.
    Muggia FM
    Semin Oncol; 1989 Apr; 16(2 Suppl 5):7-13. PubMed ID: 2655099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo and in vitro effectivity of some platinum complexes.
    Balázová E; Hrubisko M; Ujházy V
    Neoplasma; 1984; 31(6):641-7. PubMed ID: 6395026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell survival in four ovarian carcinoma xenografts following in vitro exposure to melphalan, cisplatin and cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA,JM8).
    Jones AC; Wilson PA; Steel GG
    Cancer Chemother Pharmacol; 1984; 13(2):109-13. PubMed ID: 6380788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Haematological toxicity of carboplatin in rats.
    Siddik ZH; Boxall FE; Harrap KR
    Br J Cancer; 1987 Apr; 55(4):375-9. PubMed ID: 3555590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Experimental study on carboplatin toxicity--a comparison with cisplatin].
    Suzuki K; Usami T; Sudoko H; Ohtawara Y; Tajima A; Kawabe K; Aso Y
    Gan To Kagaku Ryoho; 1988 Jul; 15(7):2153-8. PubMed ID: 3293538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A strategy for the development of two clinically active cisplatin analogs: CBDCA and CHIP.
    Foster BJ; Harding BJ; Wolpert-DeFilippes MK; Rubinstein LY; Clagett-Carr K; Leyland-Jones B
    Cancer Chemother Pharmacol; 1990; 25(6):395-404. PubMed ID: 2178792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Towards an assessment of toxicity in the treatment of ovarian cancer.
    Dones L; Wiltshaw E; Birkhead BG; Jackson RR
    Cancer Chemother Pharmacol; 1987; 20(3):213-8. PubMed ID: 3315279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative antitumour activity of cisplatin and two new cisplatin-analogues JM8 and JM9 in human testicular carcinoma xenografts.
    Harstrick A; Casper J; Schmoll HJ
    Int J Androl; 1987 Feb; 10(1):139-45. PubMed ID: 3034790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advantages in combination chemotherapy using cisplatin and its analogues for human testicular tumor xenografts.
    Hida S; Okada K; Yoshida O
    Jpn J Cancer Res; 1990 Apr; 81(4):425-30. PubMed ID: 2114395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platinum analogues in preclinical and clinical development.
    Hamilton TC; O'Dwyer PJ; Ozols RF
    Curr Opin Oncol; 1993 Nov; 5(6):1010-6. PubMed ID: 8305533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative distribution and excretion of carboplatin and cisplatin in mice.
    Siddik ZH; Jones M; Boxall FE; Harrap KR
    Cancer Chemother Pharmacol; 1988; 21(1):19-24. PubMed ID: 3277732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells.
    Alvarez-Valdés A; Pérez JM; López-Solera I; Lannegrand R; Continente JM; Amo-Ochoa P; Camazón MJ; Solans X; Font-Bardía M; Navarro-Ranninger C
    J Med Chem; 2002 Apr; 45(9):1835-44. PubMed ID: 11960495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antitumor activity and toxicity of KB-5424 R, a newly developed antitumor platinum compound].
    Yamaguchi H; Kubota T; Takahara T; Takeuchi T; Furukawa T; Kase S; Josui K; Kodaira S; Ishibiki K; Abe O
    Gan To Kagaku Ryoho; 1991 Jun; 18(7):1135-41. PubMed ID: 2053772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats.
    Siddik ZH; Newell DR; Boxall FE; Harrap KR
    Biochem Pharmacol; 1987 Jun; 36(12):1925-32. PubMed ID: 3297068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro toxicological evaluation of a dinuclear platinum(II) complex with acetate ligands.
    Momekov G; Ferdinandov D; Bakalova A; Zaharieva M; Konstantinov S; Karaivanova M
    Arch Toxicol; 2006 Sep; 80(9):555-60. PubMed ID: 16485120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bispidine analogues of cisplatin, carboplatin, and oxaliplatin. synthesis, structures, and cytotoxicity.
    Cui H; Goddard R; Pörschke KR; Hamacher A; Kassack MU
    Inorg Chem; 2014 Apr; 53(7):3371-84. PubMed ID: 24665859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of reduced osmolarity on platinum drug toxicity.
    Smith E; Brock AP
    Br J Cancer; 1989 Jun; 59(6):873-5. PubMed ID: 2660897
    [No Abstract]   [Full Text] [Related]  

  • 39. Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients.
    Sharma H; Thatcher N; Baer J; Zaki A; Smith A; McAucliffe CA; Crowther D; Owens S; Fox BW
    Cancer Chemother Pharmacol; 1983; 11(1):5-7. PubMed ID: 6349844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.